Clinical and pharmacological group: & nbsp

Alpha-blockers

Means that affect the metabolism of the prostate gland, and correctors urodynamics

Included in the formulation
  • Kornam
    pills inwards 
    Lek dd     Slovenia
  • Setegis®
    pills inwards 
  • Terazozin
    pills inwards 
  • Terazozin
    pills inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Terazozin-Teva
    pills inwards 
  • АТХ:

    G.04.C.A.03   Terazozin

    Pharmacodynamics:

    Due to the blockade of α1β-adrenoreceptors of myocytes in the walls of venules and arterioles reduces the overall peripheral resistance of the vessels, as a result of which the venous return to the heart decreases, which is manifested by lowering of arterial pressure. With regular use of patients with arterial hypertension contributes to regression of left ventricular hypertrophy.

    Selectively blocks postsynaptic α1A-adrenoceptors located on the neck of the bladder and smooth muscle cells of the prostate gland, as well as the prostatic urethra.

    It improves the outflow of urine, reduces irritation and eliminates the manifestations of obstruction of the urinary tract due to benign prostatic hyperplasia.

    Pharmacokinetics:

    After oral administration, up to 98% is absorbed in the gastrointestinal tract.The maximum concentration in the blood plasma is reached after 1 hour. The connection with plasma proteins is 90-94%.

    Metabolism in the liver.

    The half-life is 12 hours. Elimination by the kidneys and with feces.

    Indications:

    It is used to treat arterial hypertension, dysuric disorders in benign prostatic hyperplasia.

    IX.I10-I15.I15   Secondary Hypertension

    IX.I10-I15.I10   Essential [primary] hypertension

    XIV.N40-N51.N40   Hyperplasia of the prostate

    Contraindications:

    Renal and hepatic insufficiency, arterial hypotension, individual intolerance, children under 18 years of age (efficacy and safety not established).

    Carefully:

    Orthostatic hypotension, including in history, ischemic heart disease, diabetes mellitus I type, hypertensive retinopathy, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, 1 mg once before bedtime. The dose is increased gradually, but the dose should not exceed 20 mg per day.

    The highest daily dose: 20 mg per day.

    The highest single dose: 20 mg per day.

    Side effects:

    Central and peripheral nervous system: asthenia, headache, dizziness, syncope, sleep disorders.

    The cardiovascular system: orthostatic hypotension, tachycardia, cardialgia.

    Digestive system: nausea, vomiting, diarrhea, or constipation.

    Musculoskeletal system: backache.

    Sense organs: rhinitis, visual impairment.

    Dermatological reactions: a rash.

    Reproductive system: priapism, violation of libido, retrograde ejaculation.

    Allergic reactions.

    Overdose:

    Tachycardia, orthostatic collapse.

    Treatment is symptomatic.

    Interaction:

    Cimetidine increases the concentration of terazosin in the blood plasma.

    Furosemide lowers the concentration of terazosin in the blood plasma.

    Warfarin and diclofenac increase the rate of removal of terazosin.

    When used simultaneously with other α1adrenoblokatorami increases the risk of developing arterial hypotension.

    Special instructions:

    To avoid the development of orthostatic hypotension, the drug should be taken at night, while lying down.

    Before the use of terazosin, a complete examination of patients is recommended to exclude the malignant process in the prostate gland.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up